



Millendo Therapeutics, Inc. to Present at the 8th Annual SVB Leerink Global Healthcare Conference

February 21, 2019

ANN ARBOR, Mich.--(BUSINESS WIRE)--Feb. 21, 2019-- [Millendo Therapeutics, Inc.](#) (Nasdaq: MLND), a clinical-stage biopharmaceutical company developing novel treatments for orphan endocrine diseases, announced today that Julia C. Owens, Ph.D., President and Chief Executive Officer, will present at the 8th Annual SVB Leerink Global Healthcare Conference in New York City on Thursday, February 28, 2019 at 11:30 a.m. EST.

A live webcast of the presentation will be available on the Investors & Media section of Millendo's website at <http://investors.millendo.com>. A replay of the webcast will be archived on Millendo's website for 30 days following the presentation.

About Millendo Therapeutics, Inc.

Millendo Therapeutics is a late-stage biopharmaceutical company focused on developing novel treatments for orphan endocrine diseases where current therapies do not exist or are insufficient. The Company's objective is to build a leading endocrine company that creates distinct and transformative treatments for a wide range of endocrine diseases where there is a significant unmet medical need. The Company is currently advancing livoletide for the treatment of Prader-Willi syndrome and nevanimibe for the treatment of classic congenital adrenal hyperplasia and endogenous Cushing's syndrome. For more information, please visit www.millendo.com.

View source version on businesswire.com: <https://www.businesswire.com/news/home/20190221005135/en/>

Source: Millendo Therapeutics, Inc.

Millendo Investor Contact:

Stephanie Ascher
Stern Investor Relations
212-362-1200
stephanie@sternir.com

Millendo Media Contact:

Betsy Yates
MacDougall
781-235-3094
byates@macbiocom.com